Advertisement

Indian Journal of Gastroenterology

, Volume 36, Issue 3, pp 235–238 | Cite as

Relationship of hepatitis B virus infection to the recurrence of hepatocellular carcinoma after direct acting antivirals

  • Hirohito Shimizu
  • Keiji Matsui
  • Shogo Iwabuchi
  • Tomoaki Fujikawa
  • Mitsuru Nagata
  • Kentaro Takatsuka
  • Hiroyuki Tanemura
  • Haruhiro Nakazaki
  • Masayuki Nakano
  • Tsunamasa Watanabe
Short Report

Abstract

Recently, two conflicting articles about recurrence of hepatocellular carcinoma (HCC) after direct acting antivirals (DAA) against hepatitis C virus (HCV) were published. We investigated the relationship between DAA and HCC recurrence. Eligible patients were (1) history of HCC and treated curatively with interventions, and (2) interferon-free DAA therapy was initiated after eradication of HCC. We analyzed contributing factor for HCC recurrence. Ten out of 23 participants (43%) encountered recurrence of HCC. Age, sex, diabetes mellitus, fibrosis score, chemistry, and alpha-fetoprotein did not differ between patients with recurrence and patients without recurrence. The patients with recurrence had significantly higher values of antibody to hepatitis B core antigen (anti-HBc) than the patients without recurrence, 6.06±3.75 vs. 0.91±2.43 (p=0.0019). The relative risk of HCC recurrence comparing anti-HBc positive to negative was 5.2 (95% confidence interval 1.40 to 19.32). Odds ratio was 22.0 (95% confidence interval 2.5 to 191.1). We conclude that anti-HBc positivity was a strong contributing factor for HCC recurrence after DAA therapy.

Keywords

Direct acting antivirals HBc antibody Hepatitis B virus Hepatocellular carcinoma Recurrence Recurrence of HCC 

Notes

Acknowledgements

This study was supported, in part, by the Research Program on Hepatitis research from the Japan Agency for Medical Research and Development, AMED, and a grant for Practical Research on Hepatitis B from the Ministry of Health, Labour, and Welfare of Japan, and a grant-in-aid from the Ministry of Education, Culture, Sports, Science and Technology, Japan.

Compliance with ethical standards

Conflict of interest

HS, KM, SI, TF, MN, KT, HT, HN, MN, and TW declare that they have no conflict of interest.

Ethical approval

Not required, because this was a retrospective analysis of the past clinical records.

References

  1. 1.
    Reig M, Marino Z, Perello C, et al. Unexpected early tumor recurrence in patients with hepatitis C virus-related hepatocellular carcinoma undergoing interferon-free therapy. J Hepatol. 2016;65:719–26.CrossRefPubMedGoogle Scholar
  2. 2.
    Pol S. Lack of evidence of an effect of direct acting antivirals on the recurrence of hepatocellular carcinoma: the ANRS collaborative study group on hepatocellular carcinoma: Data from three ANRS cohorts. J Hepatol. 2016;65:734–40.Google Scholar
  3. 3.
    Adachi S, Shibuya A, Miura Y, Takeuchi A, Nakazawa T, Saigenji K. Impact of occult hepatitis B virus infection and prior hepatitis B virus infection on development of hepatocellular carcinoma in patients with liver cirrhosis due to hepatitis C virus. Scand J Gastroenterol. 2008;43:849–56.CrossRefPubMedGoogle Scholar
  4. 4.
    Ikeda K, Marusawa H, Osaki Y, et al. Antibody to hepatitis B core antigen and risk for hepatitis C-related hepatocellular carcinoma: a prospective study. Ann Intern Med. 2007;146:649–56.CrossRefPubMedGoogle Scholar
  5. 5.
    Nan X, Shi S, Yu C, Zhuang H. Meta-analysis of the association between anti-HBc seropositivity and a poor prognosis of chronic HCV infection. Hepatol Res. 2010;40:1176–87.CrossRefPubMedGoogle Scholar
  6. 6.
    Rehermann B, Ferrari C, Pasquinelli C, Chisari FV. The hepatitis B virus persists for decades after patients’ recovery from acute viral hepatitis despite active maintenance of a cytotoxic T-lymphocyte response. Nat Med. 1996;2:1104–8.CrossRefPubMedGoogle Scholar
  7. 7.
    Chu CM, Yeh CT, Liaw YF. Low-level viremia and intracellular expression of hepatitis B surface antigen (HBsAg) in HBsAg carriers with concurrent hepatitis C virus infection. J Clin Microbiol. 1998;36:2084–6.PubMedPubMedCentralGoogle Scholar
  8. 8.
    De Monte A, Courjon J, Anty R, et al. Direct-acting antiviral treatment in adults infected with hepatitis C virus: reactivation of hepatitis B virus coinfection as a further challenge. J Clin Virol. 2016;78:27–30.CrossRefPubMedGoogle Scholar
  9. 9.
    D’Ambrosio R, Della Corte C, Colombo M. Hepatocellular carcinoma in patients with a sustained response to anti-hepatitis C therapy. Int J Mol Sci. 2015;16:19698–712.CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Indian Society of Gastroenterology 2017

Authors and Affiliations

  • Hirohito Shimizu
    • 1
  • Keiji Matsui
    • 1
  • Shogo Iwabuchi
    • 1
  • Tomoaki Fujikawa
    • 1
  • Mitsuru Nagata
    • 1
  • Kentaro Takatsuka
    • 1
  • Hiroyuki Tanemura
    • 2
  • Haruhiro Nakazaki
    • 2
  • Masayuki Nakano
    • 3
  • Tsunamasa Watanabe
    • 1
    • 4
  1. 1.Center for Hepato-Biliary-Pancreatic and Digestive DiseaseShonan Fujisawa Tokushukai HospitalKanagawaJapan
  2. 2.Department of SurgeryShonan Fujisawa Tokushukai HospitalKanagawaJapan
  3. 3.Department of PathologyShonan Fujisawa Tokushukai HospitalKanagawaJapan
  4. 4.Division of Gastroenterology and Hepatology, Department of Internal MedicineSt. Marianna University School of MedicineKawasakiJapan

Personalised recommendations